Page 31 - 76_03
P. 31
VOL. 76 (3), 379-408, 2010 HIPOXIA Y CĂNCER
26. Greenberger, L. M., Horak, I. D., Filpula, D. et al. (2008) A RNA antagonist of
hypoxia-inducible factor alpha EZN.2968 inhibits tumor cell growth. Mol.
Cancer Ther. 7: 3598-3608.
27. Rapisarda, A., Uranchimeg, B., Sordet, O. et al. (2004) Topoisomerase I-medi-
ated inhibition of hypoxia-inducible factor alpha protein accumulation, angio-
genesis and tumor growth by topotecan in US51-HRE gliobastoma xenografts.
Cancer Res. 64: 6845-6848.
28. Rapisarda, A., Hollingshead, M., Uranchimeg, B., et al. (2009) Increased anti-
tumor activity of bevacizumab in combination with hypoxia inducible factor-1
inhibition. Mol. Cancer Ther. 8: 1867-1877.
29. Sapra, P., Zhao, H., Mehlig, M. et al. (2008) Novel delivery of SN38 markedly
inhibits tumor growth in xenographts, including a campothecin-11 refractory
model. Clin. Cancer Res. 14: 1888-1896.
30. Zhang, H., Qian, D. Z., Tan, Y. S. et al. (2008) Digoxin and other cardiac glyco-
sides inhibit HIF-alpha synthesis and block tumor growth. PNAS. 105: 19579-
19586.
31. Klausmeyer, P., Zhou, Q., Scudiero, D. A. et al. (2009) Cytotoxic and HIF-al-
pha inhibitory compounds from Cromosoma bigelovii. J. Nath. Prod. 72: 805-
812.
32. Welsh, S., Williams, R., Kirkpatrick, L. et al. (2004) Antitumor activity and phar-
macodynamic properties of PX-478 an inhibitor of hypoxia-inducible factor-1al-
pha. Mol. Cancer Ther. 3: 233-244.
33. Koh, M. Y., Spibak-Kroizman, T., Venturini, S. et al. (2008) Molecular mecha-
nisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible
factor-1alpha. Mol. Cancer Ther. 7: 90-100.
34. Wouters, B. G. & Koritzinski, M. (2008) Hypoxia signaling through mTOR and
the unfolded protein response in cancer. Nature Rev. Cancer. 8: 851-864.
35. Motzer, R. J., Bacik, J., Murphy, B. A. et al. (2002) Interferon-alpha as a com-
parative treatment for clinical trials and new therapies against advanced renal
cell carcinoma. J. Clin. Oncol. 20: 289-296.
36. Motzer, R. J., Escudier, B., Oudard, S. et al. (2008) Efficacy of everolimus in ad-
vanced renal cell carcinoma: a double blind, randomised, placebo-controlleds
phase III trial. Lancet. 372: 449-456.
37. Neckers, L. (2007) Heat shock protein 90: the cancer chaperone. J. Biosci. 32:
517-530.
38. Isaacs, J. S., Jung, Y. J., Mimnaugh, E. G. et al. (2002) HSP90 regulates a von
Hippel Lindau-independent hypoxia inducible factor-1alpha-degradative path-
way. J. Biol. Chem. 277: 29936-29944.
39. Ellis, L., Hammers, H. & Pili, R. (2009) Targeting tumor angiogenesis with hi-
stone deacetylase inhibitors. Cancer Lett. 280: 145-153.
40. Kong, D., Park, E. J., Stephen, A. G. et al. (2005) Echinomicin, a small mole-
cule inhibitor of hypoxia-inducible factor-1 DNA binding activity. Cancer Res.
65: 9047-9055.
41. Lee, K., Qian, D. Z., Rey, S. et al. (2009) Anthracycline chemotherapy inhibits
HIF-1 transcriptional activity and tumor-induced mobilization of circulating an-
giogenic cells. PNAS. 106: 2353-2358.
407
